These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36979855)

  • 1. Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure.
    Nakagaito M; Imamura T; Ushijima R; Nakamura M; Kinugawa K
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Inpatient Initiation of SGLT2 Inhibitors on Diuretic Requirements in Patients With Heart Failure.
    Cavagnini ME; Best EE; Skersick PT; Truitt KP; Musick KL; Mangum BR; Hollis IB; Rodgers JE
    J Pharm Pract; 2024 Jun; 37(3):683-689. PubMed ID: 37032494
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective association of serum adipocyte fatty acid-binding protein with heart failure hospitalization in diabetes.
    Lee CH; Kan AKC; Lui DTW; Fong CHY; Chan DSH; Yuen MMA; Chow WS; Woo YC; Xu A; Lam KSL
    ESC Heart Fail; 2021 Oct; 8(5):3964-3974. PubMed ID: 34355511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Loop Diuretic Dosing Following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure.
    Trudeau BM; Allen LA; Billups SJ; Saseen JJ; Pearson SM
    J Pharm Pract; 2023 Dec; 36(6):1330-1335. PubMed ID: 35848505
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
    Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
    Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease.
    Amioka M; Sanada R; Matsumura H; Kinoshita H; Sairaku A; Morishima N; Nakano Y
    Int J Cardiol; 2023 Jan; 370():294-299. PubMed ID: 36174820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study.
    Blanco CA; Garcia K; Singson A; Smith WR
    Perm J; 2023 Mar; 27(1):77-87. PubMed ID: 36913542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):885-890. PubMed ID: 34276019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.
    Okoroike H; Patel S; Simone P; Lavelle R; Szwak JA
    Am J Cardiol; 2023 Jan; 186():150-155. PubMed ID: 36283884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.
    Igarashi A; Maruyama-Sakurai K; Kubota A; Akiyama H; Yajima T; Kohsaka S; Miyata H
    Diabetes Ther; 2022 Jul; 13(7):1367-1381. PubMed ID: 35710646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.
    Carvalho PEP; Veiga TMA; Simões E Silva AC; Gewehr DM; Dagostin CS; Fernandes A; Nasi G; Cardoso R
    Clin Res Cardiol; 2023 Aug; 112(8):1044-1055. PubMed ID: 36592186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation.
    Oraii A; Healey JS; Benz AP; Pandey AK; Wong JA; Fonguh S; Wang J; Conen D; Gerstein HC; Connolly SJ; McIntyre WF
    Can J Cardiol; 2022 Sep; 38(9):1434-1441. PubMed ID: 35562018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.